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Purpose: To evaluate the safety and efficacy of topical recombinant human nerve growth factor (rhNGF) for
treating moderate-to-severe neurotrophic keratitis (NK), a rare degenerative corneal disease resulting from
impaired corneal innervation.
Design: Phase II multicenter, randomized, double-masked, vehicle-controlled trial.
Participants: Patients with stage 2 (moderate) or stage 3 (severe) NK in 1 eye.
Methods: The REPARO phase II study assessed safety and efficacy in 156 patients randomized 1:1:1 to
rhNGF 10 mg/ml, 20 mg/ml, or vehicle. Treatment was administered 6 drops per day for 8 weeks. Patients then
entered a 48- or 56-week follow-up period. Safety was assessed in all patients who received study treatment,
whereas efficacy was by intention to treat.
Main Outcome Measures: Corneal healing (defined as <0.5-mm maximum diameter of fluorescein
staining in the lesion area) was assessed by masked central readers at week 4 (primary efficacy end point) and
week 8 (key secondary end point) of controlled treatment. Corneal healing was reassessed post hoc by
masked central readers using a more conservative measure (0-mm staining in the lesion area and no other
persistent staining).
Results: At week 4 (primary end point), 19.6% of vehicle-treated patients achieved corneal healing (<0.5-mm
lesion staining) versus 54.9% receiving rhNGF 10 mg/ml (þ35.3%; 97.06% confidence interval [CI], 15.88e54.71;
P < 0.001) and 58.0% receiving rhNGF 20 mg/ml (þ38.4%; 97.06% CI, 18.96e57.83; P < 0.001). At week 8 (key
secondary end point), 43.1% of vehicle-treated patients achieved less than 0.5-mm lesion staining versus 74.5%
receiving rhNGF 10 mg/ml (þ31.4%; 97.06% CI, 11.25e51.49; P ¼ 0.001) and 74.0% receiving rhNGF 20 mg/ml
(þ30.9%; 97.06% CI, 10.60e51.13; P ¼ 0.002). Post hoc analysis of corneal healing by the more conservative
measure (0-mm lesion staining and no other persistent staining) maintained statistically significant differences
between rhNGF and vehicle at weeks 4 and 8. More than 96% of patients who healed after controlled rhNGF
treatment remained recurrence free during follow-up. Treatment with rhNGF was well tolerated; adverse effects
were mostly local, mild, and transient.
Conclusions: Topical rhNGF is safe and more effective than vehicle in promoting healing of moderate-
to-severe NK. Ophthalmology 2018;125:1332-1343 ª 2018 by the American Academy of Ophthalmology. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Supplemental material available at www.aaojournal.org.With approximately 7000 nerve endings per square milli-
meter, the cornea is the most densely innervated tissue in
humans.1 Corneal nerves (deriving from the trigeminal
ganglion) help maintain transparency in this avascular
tissue and participate in ocular surface homeostasis by
producing neurotrophins and facilitating sensory-
dependent corneal and tearing reflexes.1,2 Trigeminal
nerve damage may cause neurotrophic keratitis (NK) with
partial or total loss of corneal sensation, leading to visual
impairment and potentially permanent blindness. Neuro-
trophic keratitis, also known as neurotrophic keratopathy, is1332 ª 2018 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsea rare disease (estimated prevalence, 1.6e4.2 cases per
10 000 persons)3,4 with various underlying causes (most
commonly herpetic infections and ocular or neurologic
surgeries) that impair corneal innervation.5,6 Neurotrophic
keratitis diagnosis, prognosis, and treatment (reviewed
elsewhere)3,6 are based on disease severity, which is clas-
sified broadly into 3 stages.7 Briefly, stage 1 (mild) NK
exhibits ocular surface irregularity and reduced vision,
stage 2 (moderate) NK exhibits a nonhealing persistent
epithelial defect (PED), and stage 3 (severe) NK exhibits
corneal ulceration involving subepithelial (stromal) tissue,vier Inc.
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Bonini et al  rhNGF for Neurotrophic Keratitiswhich may progress to corneal perforation. All disease
stages cause some vision loss; however, if untreated,
moderate NK progresses to severe disease with associated
risks of profound vision loss resulting from scarring and
corneal perforation. Conventional therapy for stage 1 aims
to prevent epithelial breakdown, generally by
administering preservative-free artificial tears and dis-
continuing toxic topical medications. Stage 2 or 3 therapies
aim to facilitate corneal healing and prevent corneal thin-
ning (which may lead to perforation); these include sur-
geries and procedures (e.g., tarsorrhaphy, botulinum-
induced ptosis, conjunctival flap, amniotic membrane
transplantation) to restore ocular surface integrity, but
potentially sacrificing vision and cosmesis.
Strong evidence supports the treatment of NK with
neurotrophic factors.8 Nerve growth factor (NGF) has
demonstrated important roles in maintaining corneal
homeostasis in vitro, ex vivo, and in animal models.9,10
Nerve growth factor is highly conserved among verte-
brates,11 and small uncontrolled, open-label studies with
murine NGF (mNGF) produced promising results for the
treatment of corneal neurotrophic ulcers.12,13 Confirmation
of results obtained with mNGF have been highly antici-
pated14; however, nearly 2 decades passed with no approved
treatments for NK and no NGF-based treatments available
for any indication. For NK therapies in general, clinical
development has been hindered by the paucity of adequately
sized and rigorously designed studies; indeed, only 1 ran-
domized controlled trial of NK patients exists in the pub-
lished literature to date, and the investigative treatment
(topical fibronectin ophthalmic solution) was not superior to
placebo for healing PEDs.15 Thus, the natural history of NK
is not completely understood, and approved treatments are
not available for use as comparators for further studies.
For NGF in particular, translational development has been
mired by its complex tertiary structure, which complicates
the manufacturing of recombinant human NGF (rhNGF)
suitable for clinical use. To this end, we developed an
Escherichia coliederived rhNGF formulation for topical
ophthalmic use and demonstrated it to be safe and well
tolerated in phase I randomized, double-masked, vehicle-
controlled studies in healthy volunteers16 and in NK
patients.17 Herein, we report phase II study results of
topical rhNGF treatment for moderate-to-severe NK.
Methods
Clinical Trial Design
The REPARO (Latin for “repair”) trial was a phase I/II double-
masked, randomized, multicenter, vehicle-controlled, parallel-
group study that was designed to evaluate the safety and efficacy of
rhNGF eye drops (10 or 20 mg/ml, 6 drops/day for 8 weeks) in
patients with stage 2 or 3 NK. Phase I assessed safety in 18 patients
to support proceeding to phase II and was conducted, analyzed, and
reported separately.17 Phase II randomized 156 patients 1:1:1 to
rhNGF 10 mg/ml, rhNGF 20 mg/ml, or vehicle for an 8-week
controlled treatment period. Follow-up duration (48 or 56 weeks)
was determined by baseline group assignment and corneal healing
status during controlled treatment. For vehicle-treated patients,
baseline randomization included the possibility of secondaryrhNGF treatment (10 or 20 mg/ml) in the event of treatment failure
during the 8-week controlled treatment period, predefined as failure
to achieve corneal healing, recurrence of NK after healing, or
deterioration (lesion size increase of 1 mm, best-corrected dis-
tance visual acuity [BCDVA] decrease of >5 Early Treatment
Diabetic Retinopathy Study [ETDRS] letters, progression to
corneal melting or perforation, or onset of infection). This patient
subset received 8 weeks of uncontrolled treatment before
continuing follow-up (total follow-up, 56 weeks). The phase II
study design is diagrammed in Figure 1. The REPARO study
group is listed in Appendix 1 (available at www.aaojournal.org),
and the trial was registered at ClinicalTrials.gov (identifier,
NCT01756456).
Patients
Patients (18 years of age) with NK were diagnosed with stage 2
(PED) or stage 3 (corneal ulcer) disease using published criteria.7
The main inclusion criteria were evidence of decreased corneal
sensitivity within the corneal lesion and 1 or more corneal
quadrants outside the lesion; BCDVA score of 75 ETDRS letters
or fewer (0.2 logarithm of the minimum angle of resolution,
20/32 Snellen, or 0.625 decimal fraction) in the affected eye;
and no objective clinical evidence of improvement of the PED or
corneal ulcer within 2 weeks before study enrollment. The main
exclusion criteria were stage 2 or 3 NK affecting both eyes,
active ocular infection or inflammation unrelated to NK, or other
ocular disease or severe vision loss in the affected eye. For
complete inclusion and exclusion criteria, see Appendix 2
(available at www.aaojournal.org).
Efficacy Assessments
The primary efficacy variable was corneal healing, defined as less
than 0.5-mm fluorescein staining (the lower limit of reliable slit-
lamp assessment) in the lesion area, assessed in clinical pictures
by masked central readers as a yes-or-no binary variable at week 4
(primary end point) and week 8 (prespecified secondary end point).
Other secondary variables included visual acuity (BCDVA
measured in ETDRS letters), corneal sensitivity measured using the
Cochet-Bonnet aesthesiometer (CBA), and duration of corneal
healing through follow-up.
Exploratory efficacy variables included reflex tearing (Schirmer
test wetting distance after 5 minutes), time to onset of healing
(>20% reduction in maximum diameter of the corneal lesion from
baseline), and time to corneal healing (<0.5-mm lesion staining)
during the controlled or uncontrolled treatment periods. Post hoc
efficacy variables included change in lesion size and the primary
end point of corneal healing reassessed more conservatively by
masked central readers as 0-mm lesion staining and no other
persistent staining outside of the lesion.
Safety Assessments
The primary safety variable was incidence of adverse events (AEs).
Ocular tolerability was recorded by patients on a visual analog
scale (VAS) from 0 to 100 mm (0 ¼ no symptoms; 100 ¼ worst
possible discomfort) for each of 7 different symptoms: foreign
body sensation, burning or stinging, itching, ocular pain, sticky
feeling, blurred vision, and photophobia. An overall VAS score
was calculated as the mean of individual symptom scores. Other
safety parameters included visual acuity (BCDVA measured in
ETDRS letters), intraocular pressure, dilated fundus ophthalmos-
copy, vital signs, hematologic results, and clinical chemistry
results.1333
Assessed for eligibility
(N=186)
rhNGF 10 g/ml 
(N=52)
• Received controlled 
treatment (n=52)
• Withdrew before week 8 
(n=6)
o Adverse event (n=3)
o Inadequate efficacy / 
control of NK (n=2)
o Other (n=1)
• Completed 8 weeks of 
controlled treatment 
(n=46)
• Withdrew at week 8 (n=1)
o Decision unrelated to 
adverse event (n=1)
                                           
Randomized 1:1:1 at baseline
(N=156)
rhNGF 20 g/ml
(N=52)
• Received controlled 
treatment (n=52)
• Withdrew before week 8 
(n=12)
o Adverse event (n=9)
o Inadequate efficacy / 
control of NK (n=1)
o Decision unrelated to 
adverse event (n=1)
o Other (n=1)
• Completed 8 weeks of 
controlled treatment 
(n=40)
• Withdrew at week 8 (n=1)
o Other (n=1)
rhNGF 10 g/ml 
(N=10)
• Received uncontrolled 
treatment (n=10)
• Withdrew before week 8 of 
uncontrolled treatment 
(n=1)
o Adverse event (n=0)
o Inadequate efficacy / 
control of NK (n=1)
o Decision unrelated to 
adverse event (n=0)
o Other (n=0)
• Completed 8 weeks of 
uncontrolled treatment 
(n=9)
                                               
Entered 48-week follow-up 
(N=45)
• Withdrew during follow-up 
period (n=12)
o Adverse event (n=6)
o Lost to follow-up (n=4)
o Other (n=2)
• Completed 48 weeks of 
follow-up (n=33)
Entered 48-week follow-up 
(N=39)
• Withdrew during follow-up 
period (n=6)
o Adverse event (n=0)
o Lost to follow-up (n=2)
o Other (n=4)
• Completed 48 weeks of 
follow-up (n=33)
Entered 48-week follow-up 
(N=25)
• Withdrew during follow-up 
period (n=3)
o Adverse event (n=1)
o Lost to follow-up (n=1)
o Other (n=1)
• Completed 48 weeks of 
follow-up (n=22)
Continued follow-up 
(N=9)
• Withdrew during follow-up 
period (n=2)
o Adverse event (n=0)
o Lost to follow-up (n=0)
o Other (n=2)
• Completed 56 weeks of 
follow-up (n=7)
Analysis population
(N=52)
• Intention to treat (n=52)
• Safety (n=52)
Analysis population
(N=52)
• Intention to treat (n=52)
• Safety (n=52)
Analysis population
(N=52)
• Intention to treat (n=52)
• Safety (n=52)
Analysis population
(N=10)
• Intention to treat (n=10)
• Safety (n=10)
rhNGF 20 g/ml 
(N=13)
• Received uncontrolled 
treatment (n=13)
• Withdrew before week 8 of 
uncontrolled treatment 
(n=0)
o Adverse event (n=0)
o Inadequate efficacy / 
control of NK (n=0)
o Other (n=0)
• Decision unrelated to 
adverse event (n=0)
• Completed 8 weeks of 
uncontrolled treatment 
(n=13)
                                               
Continued follow-up 
(N=13)
• Withdrew during follow-up 
period (n=4)
o Adverse event (n=0)
o Lost to follow-up (n=1)
o Other (n=3)
• Completed 56 weeks of 
follow-up (n=9)
Analysis population
(N=13)
• Intention to treat (n=13)
• Safety (n=13)
 Entered 56-week follow-up*
(N=23)
Allocated according to secondary baseline randomization 
(N=23)
Ineligible
(N=12)
Phase I
(N=18)
 Phase II
(N=156)
Vehicle control
(N=52)
• Received controlled 
treatment (n=52)
• Withdrew before week 8 
(n=4)
o Adverse event (n=1)
o Decision unrelated to 
adverse event (n=1)
o Other (n=2)
• Entered 56-week follow-up 
before week 8 (n=8)*
• Completed 8 weeks of 
controlled treatment 
(n=40)
o Entered 56-week follow-
up at week 8 (n=15)*
Figure 1. Diagram showing the REPARO phase II study design and overall patient disposition. The REPARO phase II study enrolled 156 patients with
neurotrophic keratitis (NK) of severity stage 2 (persistent epithelial defect) or stage 3 (corneal ulcer). Patients were randomized 1:1:1 to 10 mg/ml re-
combinant human nerve growth factor (rhNGF), 20 mg/ml rhNGF, or vehicle and received 8 weeks of controlled treatment and 48 weeks of follow-up. *A
56-week follow-up period was intended for vehicle-treated patients who experienced treatment failure (see Clinical Trial Design section for details) and
included 8 weeks of uncontrolled treatment with 10 or 20 mg/ml rhNGF (dosage assigned at baseline in a secondary randomization scheme) before
continuing follow-up for 48 weeks.
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Assessments
Blood samples were collected for pharmacokinetics profiling and
immunogenicity assessments (anti-NGF antibody shifts from
baseline to after baseline), performed using enzyme-linked
immunosorbent assay as described previously.16
Masking and Statistical Analysis
Patients, investigators, and site or sponsor staff were masked to
primary randomized treatment and to the dosage of randomized
secondary treatment. Indistinguishable kits for dispensing rhNGF
or vehicle were assigned randomly according to numbers generated
by Statistical Analysis System programmers not directly involved
in study analysis. The sponsor was not involved in efficacy data
collection for masked central analysis. Assessments by the central
reading center were masked to treatment assignment and duration.
Unmasking was restricted to final statistical analysis (after database
lock) and medical emergencies, including NK recurrence or1334deterioration. A clinical research organization maintained the
masked database and performed statistical analyses.
Based on the only published randomized controlled trial of
NK15 and uncontrolled studies of mNGF-treated NK patients,12,13
60% of rhNGF-treated patients were estimated to achieve less than
0.5-mm lesion staining at 4 weeks (vs. 30% in vehicle-treated
patients). Although the study’s exploratory nature did not war-
rant adjustment for multiple comparisons, 2-sided significance of
chi-square testing was adjusted to the Pocock threshold (a ¼
0.0294),18 yielding a 97.06% confidence interval (CI) for the
primary efficacy end point of corneal healing. According to this
methodology, phase II required 141 evaluable patients to have
80% power to detect this difference in the primary efficacy
variable, and 156 patients assuming a 10% to 20% dropout rate.
Efficacy analyses were performed on intention-to-treat pop-
ulations, with missing data after baseline using the last observation
carried forward. Also conducted were observed-case analyses and
sensitivity analyses, with missing observations after baseline
imputed as failures and by multiple imputation procedures MI
and MIANALYZE in SAS software (SAS Institute, Cary, NC).
Table 1. Patient Demographics and Baseline Characteristics
Characteristics
Recombinant Human Nerve Growth Factor
Vehicle (N [ 52)10 mg/ml (N ¼ 52) 20 mg/ml (N ¼ 52)
Age (yrs)
Mean (SD) 59.0 (17.17) 62.5 (14.01) 60.4 (16.78)
Median (minimumemaximum) 61.5 (20e87) 63.5 (18e95) 60.5 (23e91)
Female gender, no. (%) 30 (57.7) 30 (57.7) 35 (67.3)
Ethnicity, no. (%)
Hispanic, Latino, or Spanish 6 (11.5) 9 (17.3) 5 (9.6)
N/A 4 (7.7) 1 (1.9) 6 (11.5)
Race, no. (%)
Asian 1 (1.9) 0 1 (1.9)
Black 0 0 1 (1.9)
White 46 (88.5) 51 (98.1) 45 (86.5)
N/A 5 (9.6) 1 (1.9) 5 (9.6)
Primary NK diagnosis, no. (%)
Stage 2 21 (40.4) 27 (51.9) 28 (53.8)
Stage 3 31 (59.6) 25 (48.1) 24 (46.2)
Underlying cause, no. (%)
Diabetes mellitus 3 (5.8) 4 (7.7) 4 (7.7)
Dry eye disease 6 (11.5) 6 (11.5) 5 (9.6)
Herpetic eye disease* 15 (28.8) 11 (21.2) 18 (34.6)
Neurosurgical procedure
Acoustic neuroma 2 (3.8) 1 (1.9) 3 (5.8)
Auditive neurosurgery 0 1 (1.9) 0
Cerebellar metastasis 0 1 (1.9) 0
Cerebral epidermoid cyst aspiration 0 1 (1.9) 0
Craniotomy for glioma 1 (1.9) 0 0
Facial nerve reconstruction 1 (1.9) 0 0
Meningioma excision 0 1 (1.9) 1 (1.9)
Schwannoma 1 (1.9) 1 (1.9) 3 (5.8)
Unspecified 1 (1.9) 2 (3.8) 0
Nonviral infection
Amoebic keratitis 0 2 (3.8) 0
Unspecified 1 (1.9) 0 1 (1.9)
Ocular surface injury/inflammation
Chemical burn 4 (7.7) 2 (3.8) 3 (5.8)
Unspecified 1 (1.9) 3 (5.8) 2 (3.8)
Ocular surgery or procedure
Cataract surgery/scleral buckle/vitrectomy 1 (1.9) 1 (1.9) 1 (1.9)
Corneal transplantation 0 0 1 (1.9)
Keratoplasty 2 (3.8) 0 0
Maxillofacial surgery (eyelid suture) 1 (1.9) 0 0
Strontium brachytherapy, mitomycin drops 0 0 1 (1.9)
Unspecified 5 (9.6) 4 (7.7) 4 (7.7)
Other
Atopic dermatitis 1 (1.9) 0 0
Corneal hypoesthesia 0 1 (1.9) 0
Facial palsy resulting from measles 1 (1.9) 0 0
Goldenhar syndrome 0 0 1 (1.9)
Graves-Basedow disease 0 1 (1.9) 0
Lagophthalmos 0 0 1 (1.9)
Miller-Fisher syndrome 1 (1.9) 0 0
Multifactorial (HSV, keratoplasty, burn, diabetes) 0 1 (1.9) 0
Neurovascular encephalopathy 0 1 (1.9) 0
Paraneoplastic neuropathy (lung cancer) 0 1 (1.9) 0
Pemphigoid 0 1 (1.9) 1 (1.9)
Polyneuropathy, traumatic erosion 0 1 (1.9) 0
Stroke 1 (1.9) 2 (3.8) 0
Systemic medication 1 (1.9) 0 0
Topical medication (glaucoma medication) 0 1 (1.9) 1 (1.9)
Unknown origin 1 (1.9) 1 (1.9) 0
(Continued)
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Table 1. (Continued.)
Characteristics
Recombinant Human Nerve Growth Factor
Vehicle (N [ 52)10 mg/ml (N ¼ 52) 20 mg/ml (N ¼ 52)
Venous sinus thrombosis 1 (1.9) 0 0
Viral conjunctivitis (unspecified) 0 0 1 (1.9)
HSV ¼ herpes simplex virus; N/A ¼ not available (ethnicity and race were not collected in all countries); NK ¼ neurotrophic keratitis; SD ¼ standard
deviation.
*Includes herpes simplex, herpes zoster, and recurrent herpetic keratitis.
Ophthalmology Volume 125, Number 9, September 2018For binary secondary and exploratory efficacy end points,
2-sided significance was set at a ¼ 0.05. Change in BCDVA score
from baseline to week 8 was analyzed by an analysis of covariance
model using treatment group and baseline BCDVA score. Mixed-
effects repeated-measures models using treatment, visit, and
baseline measurements were used to assess changes in lesion size
(maximum dimension) and reflex tearing (Schirmer test wetting
distance) from baseline to weeks 4 and 8. The time to onset of
healing (>20% reduction in maximum diameter of the corneal
lesion from baseline) and corneal healing (<0.5-mm maximum
diameter of fluorescein staining) were analyzed using Kaplan-
Meier methods and the log-rank test (for the controlled treatment
period) and descriptive statistics (for the uncontrolled treatment
period). Data collected during follow-up also were analyzed using
descriptive statistics.Study Oversight
Approval was obtained for the study protocol, amendments, and
study-related documents (including informed consent) from the
institutional review board of Sapienza University of Rome and an
independent ethics committee from each country with 1 or more
participating sites (Appendix 1, available at www.aaojournal.org).
The study complied with the Declaration of Helsinki, relevant parts
of the Code of Federal Regulations Title 21, and good clinical
practice and good laboratory practice guidelines. Written
informed consent was obtained before study-related procedures.
Compliance was assessed at each visit and verified by study
monitors during onsite visits.Results
Patients and Treatment
The REPARO investigators (Appendix 1, available at
www.aaojournal.org) represented 39 sites in 9 European countries
(Belgium, France, Germany, Hungary, Italy, Poland, Portugal,
Spain, and the United Kingdom); 32 sites in 6 countries enrolled 1
or more patients. Figure 1 provides an overview of patient
disposition (including reasons for withdrawal). Of 186 patients
screened from January 2013 through May 2015, 174 were
enrolled: 18 in phase I17 and 156 in phase II. Patient demographics
and baseline characteristics were well balanced in the REPARO
phase II study, with no clinically notable differences between
treatment groups (Table 1). Consistent with published
literature,5,6,13,19 common underlying causes included herpetic eye
disease (44 patients) and ocular or neurologic surgery (21 patients
each). Prior treatments for NK (most commonly artificial tears, gels,
or ointments and topical antibiotics) are listed in Appendix 3
(available at www.aaojournal.org).1336Efficacy Outcomes
Table 2 summarizes efficacy analyses at weeks 4 and 8 (last
observation carried forward). Corneal healing (<0.5-mm lesion
staining) was achieved at week 4 (primary end point) in 19.6% of
vehicle-treated patients versus 54.9% receiving rhNGF 10 mg/ml
(þ35.3%; 97.06% CI, 15.88%e54.71%; P < 0.001) and 58.0%
receiving rhNGF 20 mg/ml (þ38.4%; 97.06% CI, 18.96%e
57.83%; P< 0.001). Corneal healing at week 8 (key secondary end
point) was achieved in 43.1% of vehicle-treated patients versus
74.5% receiving rhNGF 10 mg/ml (þ31.4%; 97.06% CI, 11.25%e
51.49%; P ¼ 0.001) and 74.0% receiving rhNGF 20 mg/ml
(þ30.9%; 97.06% CI, 10.60%e51.13%; P ¼ 0.002). Table 3
summarizes the post hoc reanalysis of corneal healing using the
more conservative definition (0-mm lesion staining and no other
persistent staining). This confirmed statistically significant differ-
ences between rhNGF and vehicle, with consistently higher per-
centages healed in the rhNGF 20-mg/ml group at both week 4 and
week 8. Observed-case, worst-case (missing observations after
baseline imputed as failures), and multiple imputation analyses
produced similar results (not shown). Differences between rhNGF
groups were not statistically significant.
Figure 2A shows representative images of corneal fluorescein
staining at baseline through week 8. Lesion size changes from
baseline (determined by the reading center) were analyzed post
hoc for clinically significant differences between treatments (Fig
2B). At week 4, least squares mean lesion size change from
baseline was 49.8% with rhNGF 20 mg/ml, 39.5% with rhNGF
10 mg/ml, and 8.9% with vehicle. At week 8, lesion size change
was 76.0% with rhNGF 20 mg/ml, 58.4% with rhNGF 10 mg/ml,
and 26.2% with vehicle. Overall, rhNGF-treated patients exhibi-
ted greater (but statistically nonsignificant) lesion size reductions
from baseline versus vehicle-treated patients, trending toward
significance in rhNGF 20 mg/ml versus vehicle at week 8 (P ¼
0.102; 95% CI, e109.61% to 9.98%).
Visual acuity outcomes were assessed as changes from baseline
to week 8. As shown in Figure 3, compared with vehicle-treated
patients, least squares mean change in BCDVA score (ETDRS
letters) from baseline to week 8 was significantly different in pa-
tients receiving rhNGF 10 mg/ml (P ¼ 0.022), but not in those
receiving rhNGF 20 mg/ml (P ¼ 0.213). However, the difference
between rhNGF doses was not significant (P ¼ 0.305). Best-
corrected distance visual acuity assessed as a gain of 15 ETDRS
letters (yes or no) from baseline to week 8 produced similar results
(Table 4). Compared with vehicle, 15-letter gains were achieved by
more patients receiving rhNGF 10 mg/ml (þ27.5%; 95% CI,
8.33%e46.67%; P ¼ 0.008) and rhNGF 20 mg/ml (þ19%; 95%
CI, 0.91%e38.83%; P ¼ 0.068), with no statistically significant
difference between rhNGF doses (P ¼ 0.421).
Corneal sensitivity during the controlled treatment period was
measured directly in the corneal lesion and outside quadrants using
the CBA as secondary efficacy variable, and indirectly by Schirmer
Table 2. Primary Efficacy Analysis of Corneal Healing (<0.5-mm Lesion Staining)
Results
Recombinant Human Nerve Growth Factor
Vehicle (N [ 52)*10 mg/ml (N ¼ 52)* 20 mg/ml (N ¼ 52)*
Healed at week 4, no. (%) 28/51 (54.9) 29/50 (58.0) 10/51 (19.6)
Difference (rhNGF e vehicle), % 35.3 38.4
97.06% CI 15.88e54.71 18.96e57.83
P value <0.001 <0.001
Difference (rhNGF 20 mg/ml e rhNGF 10 mg/ml), % 3.1
97.06% CI e18.38 to 24.58
P value 0.754
Healed at week 8, no. (%) 38/51 (74.5) 37/50 (74.0) 22/51 (43.1)
Difference (rhNGF e vehicle), % 31.4 30.9
97.06% CI 11.25e51.49 10.60e51.13
P value 0.001 0.002
Difference (rhNGF 20 mg/ml e rhNGF 10 mg/ml), % e0.5
97.06% CI e19.46 to 18.44
P value 0.953
CI ¼ confidence interval; rhNGF ¼ recombinant human nerve growth factor.
*Number of patients randomized to each treatment.
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vehicle, more patients receiving rhNGF 10 or 20 mg/ml exhibited
improvement in corneal sensitivity (measured by CBA) from base-
line to weeks 4 and 8, but the differences between treatment groups
were not significant (Table S5, available online at
www.aaojournal.org). Figure S4 (available at www.aaojournal.org)
shows results of Schirmer tests of reflex tearing. Least squares
mean change from baseline was greater in the rhNGF-treated
groups compared with those receiving vehicle, with differences
reaching statistical significance between rhNGF 10 mg/ml and
vehicle groups at week 4 (P ¼ 0.047) and week 8 (P ¼ 0.010).
Comparisons between patients receiving rhNGF 20 mg/ml and
vehicle were not significant at week 4 (P ¼ 0.234) or week 8 (P ¼
0.201). However, comparisons between rhNGF doses also were not
significant at either week 4 (P ¼ 0.442) or week 8 (P ¼ 0.191).
Figure 5 illustrates exploratory Kaplan-Meier analyses of
time-to-event variables for the controlled treatment period. TheTable 3. Post Hoc Efficacy Analysis of Corneal Healing (
Results
Recom
10 mg/ml (N
Healed at week 4, no. (%) 25/51
Difference (rhNGF e vehicle), % 35.3
97.06% CI 16.78e
P value <0.0
Difference (rhNGF 20 mg/ml e rhNGF 10 mg/ml), % 9.0
97.06% CI e12.55 t
P value 0.3
Healed at week 8, no. (%) 32/51 (
Difference (rhNGF e vehicle), % 29.4
97.06% CI 8.82e5
P value 0.0
Difference (rhNGF 20 mg/ml e rhNGF 10 mg/ml), % 9.3
97.06% CI e10.96 t
P value 0.3
CI ¼ confidence interval; rhNGF ¼ recombinant human nerve growth factor.
*Number of patients randomized to each treatment.median time to onset of healing (20% reduction in maximum
lesion diameter from baseline), which was 14 days in patients
receiving vehicle (95% CI, 14e28 days), compared with 8 days
in patients receiving rhNGF 10 mg/ml (95% CI, 7e14 days; P ¼
0.002) and 14 days in patients receiving rhNGF 20 mg/ml (95%
CI, 7e14 days; P ¼ 0.015). For time to corneal healing (<0.5-
mm lesion staining), median time was 56 days (95% CI, 42
daysenot estimable) in patients receiving vehicle, compared
with 29 days in patients receiving rhNGF 10 mg/ml (95% CI,
20e55 days; P ¼ 0.002) and 28 days in patients receiving
rhNGF 20 mg/ml (95% CI, 19e55 days; P ¼ 0.002).
Follow-up data (not powered for efficacy analyses) are pre-
sented using descriptive statistics. Of patients receiving vehicle
during 8-week controlled treatment, 23 experienced treatment
failure (failure to achieve corneal healing, recurrence of NK after
healing, or deterioration) and entered the 56-week follow-up
period, which included 8 weeks of uncontrolled rhNGF treatment0-mm Lesion Staining, No Other Persistent Staining)
binant Human Nerve Growth Factor
Vehicle (N [ 52)*¼ 52)* 20 mg/ml (N ¼ 52)*
(49) 29/50 (58) 7/51 (13.7)
44.3
53.80 25.80e62.75
01 <0.001
o 30.51
66
62.7) 36/50 (72.0) 17/51 (33.3)
38.7
0.01 18.72e58.62
03 <0.001
o 29.47
21
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Figure 2. Images showing assessment of corneal lesion size on clinical pictures. A, Representative images showing the progression of a typical oval, par-
acentral, neurotrophic corneal lesion from baseline through week 8 in a patient treated with 20 mg/ml recombinant human nerve growth factor (rhNGF).
Top row, Photographs of the cornea illuminated with diffuse white light. Bottom row, Corneal lesion healed at week 8 as assessed by the central reading
center on fluorescein staining (green) photographs obtained under cobalt-blue light illumination. B, Bar graph showing post hoc analysis of least squares
mean percentage change from baseline in maximum dimension of persistent epithelial defect or corneal ulcer after the 8-week controlled treatment period.
Error bars represent standard error. Magnitude change in lesion size was greater in patients in the rhNGF treatment groups compared with the vehicle group
(not reaching statistical significance), with a trend toward significance in 20 mg/ml rhNGF versus vehicle treatment at week 8 (P ¼ 0.102; 95% confidence
interval, e109.61 to 9.98).
Ophthalmology Volume 125, Number 9, September 2018(Fig 1). Per a secondary baseline randomization scheme, 10
patients received 10 mg/ml rhNGF and 13 received 20 mg/ml
rhNGF. At the end of uncontrolled treatment, corneal healing
(<0.5-mm lesion staining, assessed by the investigator) was ach-
ieved in 3 of 10 patients (30%) receiving 10 mg/ml rhNGF and in 8
of 13 patients (61.5%) receiving 20 mg/ml rhNGF. Figure S6
(available at www.aaojournal.org) shows Kaplan-Meier plots of
time-to-event variables for the 8-week uncontrolled treatment
portion of the 56-week follow-up period. Onset of healing was
assessed as 20% reduction in maximum lesion diameter from the
last measurement of the controlled treatment period. Median time
to onset of healing was 14.5 days (range, 7e55 days) in the 10-mg/
ml rhNGF group and 7 days (range, 7e42 days) in the 20-mg/ml
rhNGF group. Median time to corneal healing (<0.5-mm lesion1338staining) in the 10-mg/ml rhNGF group was 15 days (range, 14e27
days) and 21 days (range, 7e42 days) in the 20-mg/ml rhNGF
group.
Of patients who achieved corneal healing (<0.5-mm lesion
staining) and completed follow-up, very few experienced recur-
rence of the PED or corneal ulcer. Of those who healed after
controlled treatment and completed 48-week follow-up, recurrence
was experienced by 1 of 20 patients in the vehicle group (4.8%), 1
of 27 patients in the rhNGF 10-mg/ml group (3.6%), and 1 of 28
patients in the rhNGF 20-mg/ml group (3.4%). Of patients who
healed after uncontrolled treatment and completed 56 weeks of
follow-up, recurrence was experienced by 0 of 4 patients in the
rhNGF 10-mg/ml group and 2 of 6 patients (33%) in the rhNGF 20-
mg/ml group.
0 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
Vehicle 
rhNGF 10 µl/ml 
rhNGF 20 µl/ml 
LS
m
ea
n 
C
ha
ng
e 
fro
m
 B
as
el
in
e 
Figure 3. Bar graph showing secondary efficacy analysis of visual acuity
score during controlled treatment. Least squares mean (LSmean) change
from baseline in best-corrected distance visual acuity measured in Early
Treatment Diabetic Retinopathy Study letters was analyzed using an
analysis of covariance model (treatment þ baseline score). Compared with
vehicle-treated patients, LSmean change from baseline to week 8 was
greater in the rhNGF-treated groups, with the difference reaching statistical
significance between patients receiving vehicle and those receiving 10 mg/ml
recombinant human nerve growth factor (rhNGF; P ¼ 0.022), but not
20 mg/ml rhNGF (P ¼ 0.213). However, the comparison between rhNGF
doses also was not significant (P ¼ 0.305).
Bonini et al  rhNGF for Neurotrophic KeratitisSafety Outcomes
Table 6 summarizes treatment-related AEs during controlled
treatment, which occurred in 25 patients: 6 (11.5%) receiving
rhNGF 10 mg/ml, 9 (17.3%) receiving rhNGF 20 mg/ml, and 10
(19.2%) receiving vehicle. Two patients receiving rhNGF 10 mg/
ml, 9 receiving rhNGF 20 mg/ml, and 4 receiving vehicle experi-
enced AEs leading to discontinuation of study treatment. Addi-
tional phase II safety results (treatment-related AEs during
uncontrolled treatment and follow-up periods) are presented in
Appendix 4 (available at www.aaojournal.org). Overall, 17 patients
(10.9%) experienced serious AEs during controlled treatment: 3Table 4. Secondary Efficacy Analysis of Patients Achieving 1
Results
Recom
10 mg/ml (N
15-letter gain in BCDVA at week 4, no. (%) 18/49 (
Difference (rhNGF e vehicle), % 15.8
95% CI e2.36 to
P value 0.0
Difference (rhNGF 20 mg/ml e rhNGF 10 mg/ml), % e2.6
95% CI e22.41 t
P value 0.7
15-letter gain in BCDVA at week 8, no. (%) 24/48 (
Difference (rhNGF e vehicle), % 27.5
95% CI 8.33e4
P value 0.0
Difference (rhNGF 20 mg/ml e rhNGF 10 mg/ml), % e8.5
95% CI e29.21 t
P value 0.4
BCDVA ¼ best-corrected distance visual acuity; CI ¼ confidence interval; rhN
Patients without a yes-or-no response available at week 4 and week 8 are not c
*Number of patients randomized to each treatment.receiving rhNGF 10 mg/ml, 9 receiving rhNGF 20 mg/ml, and 5
receiving vehicle. No serious AEs were considered related to
study treatment.
Changes from baseline VAS scores were analyzed by repeated-
measures analysis of covariance (controlled treatment period) or
descriptive statistics (follow-up period). Decreases in VAS scores
were observed in all groups, indicating improvement in ocular
tolerability, but differences between groups were not statistically
significant for the controlled treatment period or otherwise note-
worthy during follow-up.
Patients whose NK worsened during the study were dis-
continued (and respective treatments unmasked) per protocol. Of
vehicle-treated patients, 12 experienced deterioration (2 patients at
week 4, 4 patients at week 6, and 6 patients at week 8), versus 4
receiving rhNGF 10 mg/ml (1 patient at week 4, 1 patient at week 6,
and 2 patients at week 8) and 4 receiving rhNGF 20 mg/ml (1
patient at week 4, no patients at week 6, and 3 patients at week 8).
Eight deaths were reported during the study: 2 during controlled
treatment (1 receiving rhNGF 10 mg/ml and 1 receiving rhNGF 20
mg/ml) and 6 during follow-up (4 patients in the rhNGF 10-mg/ml
group and 1 each in the 20-mg/ml and vehicle groups). All events
leading to death (Appendix 4, available at www.aaojournal.org)
were considered unrelated to study treatment.
Pharmacokinetics and Immunogenicity
As shown in Figure S7 (available at www.aaojournal.org), only 5
patients (3 receiving rhNGF 10 mg/ml and 2 receiving rhNGF 20
mg/ml) demonstrated serum NGF concentrations more than the
lower limit of quantification of 32.000 pg/ml at any time point
tested. Consistent with phase I studies of rhNGF,16,17 these re-
sults likely represent individual fluctuations of endogenous NGF
independent of study treatment. No anti-NGF antibodies were
detected at any time point during controlled or uncontrolled
treatment periods or follow-up.
Discussion
This study demonstrated that topical rhNGF safely and
effectively improves corneal epithelial integrity in moderate5-Letter Gains in Best-Corrected Distance Visual Acuity
binant Human Nerve Growth Factor
Vehicle (N [ 52)*¼ 52)* 20 mg/ml (N ¼ 52)*
36.7) 14/41 (34.1) 9/43 (20.9)
13.2
33.97 e5.72 to 32.15
97 0.175
o 17.23
98
50.0) 17/41 (41.5) 9/40 (22.5)
19.0
6.67 e0.91 to 38.83
08 0.068
o 12.14
21
GF ¼ recombinant human nerve growth factor.
onsidered in this table. The significance level is 0.05.
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Figure 5. Exploratory analyses of Kaplan-Meier time-to-event variables during controlled treatment. A, Median time to onset of healing (>20% reduction
in maximum diameter of the corneal lesion from baseline) was 14 days in patients receiving vehicle (95% confidence interval [CI], 14e28 days), versus 8
days in patients receiving rhNGF 10 mg/ml (95% CI, 7e14 days; P ¼ 0.002) and 14 days in patients receiving rhNGF 20 mg/ml (95% CI, 7e14 days; P ¼
0.015). B, Median time to corneal healing (<0.5-mm lesion staining) was 56 days (95% CI, 42 daysenot estimable) in patients receiving vehicle, versus 29
days in patients receiving rhNGF 10 mg/ml (95% CI, 20e55 days; P ¼ 0.002) and 28 days in patients receiving rhNGF 20 mg/ml (95% CI, 19e55 days; P ¼
0.002). rhNGF ¼ recombinant human nerve growth factor.
Ophthalmology Volume 125, Number 9, September 2018to severe NK, confirming results achieved using mNGF.12,13
Although previous reports demonstrated clinical effective-
ness of mNGF 200 mg/ml,12,13 preclinical pharmacologic
tests demonstrated higher potency of E. coliederived
rhNGF versus mNGF: notably, higher affinity for human
TrkA (high-affinity NGF receptor) and approximately 10-
fold potency in inducing proliferation of human TF1 cells
expressing TrkA (Dompé Farmaceutici SpA, unpublished
data, 2012). Thus, rhNGF 20 mg/ml was selected as the
equivalent therapeutic dose, and 10 mg/ml (lowest concen-
tration compatible with analytical and manufacturing re-
quirements) for dose-response purposes. Both rhNGF doses
demonstrated robust efficacy results of corneal healing after13404 to 8 weeks of treatment. Healing was maintained through
follow-up for more than 96% of rhNGF-treated patients.
The use of intense topical lubricants and close follow-up
in vehicle-treated patients showed the natural course of NK
using this conservative treatment approach. A subset of
patients receiving constant lubrication with vehicle for up to
8 weeks demonstrated epithelial regrowth and closure of an
NK lesion; however, lubrication alone may have a higher
risk of disease progression and persistence of a small
corneal lesion (<0.5 mm), which may pose a risk of com-
plications (e.g., superinfection and a relapse to more severe
NK). Because healthy corneas may demonstrate some de-
gree of corneal staining,20 we compared 2 different
Table 6. Summary of Treatment-Related Adverse Events* by System Organ Class and Preferred Term (Controlled Treatment Period)
Body System (MedDRA Preferred Term)
Recombinant Human Nerve Growth Factor
Vehicle (N [ 52)y10 mg/ml (N ¼ 52)y 20 mg/ml (N ¼ 52)y
No. of Events
Reported
No. of Patients
(%)
No. of Events
Reported
No. of Patients
(%)
No. of Events
Reported
No. of Patients
(%)
Any adverse event 10 6 (11.5) 15 9 (17.3) 20 10 (19.2)
Eye disorders 7 5 (9.6) 10 7 (13.5) 16 9 (17.3)
Eye pain 0 0 4 4 (7.7) 3 2 (3.8)
Blepharitis 1 1 (1.9) 1 1 (1.9) 1 1 (1.9)
Corneal neovascularization 0 0 1 1 (1.9) 1 1 (1.9)
Eye irritation 1 1 (1.9) 0 0 1 1 (1.9)
Eye pruritus 0 0 1 1 (1.9) 1 1 (1.9)
Vision blurred 0 0 0 0 2 2 (3.8)
Abnormal sensation in eye 0 0 0 0 1 1 (1.9)
Asthenopia 0 0 0 0 1 1 (1.9)
Conjunctival hyperemia 0 0 0 0 1 1 (1.9)
Corneal deposits 0 0 1 1 (1.9) 0 0
Corneal epithelium defect 0 0 0 0 1 1 (1.9)
Dry eye 0 0 0 0 1 1 (1.9)
Eye discharge 1 1 (1.9) 0 0 0 0
Eyelid edema 0 0 0 0 1 1 (1.9)
Eyelid pain 2 1 (1.9) 0 0 0 0
Lacrimation increased 1 1 (1.9) 0 0 0 0
Macular fibrosis 0 0 1 1 (1.9) 0 0
Ocular hyperemia 0 0 0 0 1 1 (1.9)
Photophobia 1 1 (1.9) 0 0 0 0
Visual acuity reduced 0 0 1 1 (1.9) 0 0
General disorders and administration site conditions 1 1 (1.9) 0 0 3 3 (5.8)
Disease progressionz 1 1 (1.9) 0 0 2 2 (3.8)
Instillation site pain 0 0 0 0 1 1 (1.9)
Nervous system disorders 2 2 (3.8) 1 1 (1.9) 1 1 (1.9)
Headache 1 1 (1.9) 1 1 (1.9) 1 1 (1.9)
Neuralgia 1 1 (1.9) 0 0 0 0
Blood and lymphatic system disorders 0 0 1 1 (1.9) 0 0
Neutropenia 0 0 1 1 (1.9) 0 0
Cardiac disorders 0 0 1 1 (1.9) 0 0
Arrhythmia 0 0 1 1 (1.9) 0 0
Infections and infestations 0 0 1 1 (1.9) 0 0
Corneal abscess 0 0 1 1 (1.9) 0 0
Investigations 0 0 1 1 (1.9) 0 0
Blood pressure increased 0 0 1 1 (1.9) 0 0
MedDRA ¼ Medical Dictionary for Regulatory Activities.
Percentages are calculated using the population number in each treatment group as the denominator.
*Treatment-related adverse events are those events recorded by the investigator as having a possible, probable, or highly probable relationship to study
treatment.
yNumber of patients who received each treatment in the specified study period.
zDisease progression was defined as increase in lesion size of 1 mm or more, decrease in best-corrected distance visual acuity by more than 5 Early Treatment
Diabetic Retinopathy Study letters, progression in lesion depth to corneal melting or perforation, or onset of infection.
Bonini et al  rhNGF for Neurotrophic Keratitisdefinitions of corneal healing. Our results suggest that the
more conservative measure of corneal healing (0-mm
lesion staining and no other persistent staining) is more
reliable than the conventional measure (<0.5-mm lesion
staining) for evaluating corneal healing. Although both
measures produced consistent results, the more conservative
assessment showed more consistent differences between
rhNGF and vehicle, allowing more definitive discrimination
of treatment effect.
Clinical efficacy of topical rhNGF for treating NK also
was supported by improvement on other clinically relevant
end points, including corneal lesion size, time to corneal
healing (or onset of healing), BCDVA, corneal sensitivitymeasured by CBA, and reflex tearing (which also may reflect
corneal sensitivity not detectable by CBA). Although we did
not observe statistically significant differences between both
rhNGF doses and vehicle in these variables at every time
point, the sample size was based on the dichotomous (yes-or-
no) primary end point and was not powered to detect small
but clinically significant differences in secondary, explor-
atory, or post hoc variables. To this point, the rhNGF 10-mg/
ml group (but not the rhNGF 20-mg/ml group) exhibited
statistically significant differences compared with the vehicle
group in some secondary end points (such as visual acuity
and reflex tearing); however, for the same end points, dif-
ferences between rhNGF doses did not reach statistical1341
Ophthalmology Volume 125, Number 9, September 2018significance. Thus, it is difficult to draw conclusions on dose
responsiveness. Nonetheless, patients receiving rhNGF
generally had better trends of improvement for most efficacy
end points versus patients receiving vehicle.
Visual acuity was assessed as a secondary efficacy end
point, although it does not necessarily reflect NK severity or
healing status. For example, in stage 2 NK, absence of the
epithelium may have little or no impact on vision, whereas
re-epithelialization in the central or paracentral cornea can
cause optical aberrations (and hence reduced vision).
Figure 2A illustrates this latter point; it would not be
surprising that this patient still had reduced vision after 8
weeks of controlled rhNGF 20-mg/ml treatment, despite
achieving corneal healing with 0-mm lesion staining and
no other persistent staining.
No safety concerns arose; most AEs were ocular, mild,
and transient and did not require discontinuing or corrective
treatments. The predominant treatment-related AE was eye
pain; others included abnormal sensation in the eye, excess
lacrimation, photophobia, eyelid pain, and eye or eyelid
irritation, which may reflect therapeutic actions of rhNGF
and normal healing. Indeed, restoring corneal innervation
and sensitivity (which, in turn, will promote corneal healing)
can be associated with increased ocular surface symptoms.
No immunogenicity to NGF was detected in this study;
furthermore, consistent with phase I results,16,17 most pa-
tients showed undetectable serum NGF, no systemic AEs, or
both. Taken together, these pharmacokinetic and immuno-
genicity results suggest unlikely systemic absorption or
accumulation of topical ophthalmic rhNGF.
Neurotrophic keratitis is a challenging disease with a
high unmet need for treatments that improve corneal
sensitivity (which is crucial for restoring corneal epithelial
integrity) and promote healing without surgery or compro-
mising vision. In this study, topical rhNGF demonstrated
favorable benefit-to-risk ratios for patients with moderate-
to-severe NK, confirming that rhNGF is a feasible approach
to treating NK. The neuroprotective effects of rhNGF also
may be extended to other ophthalmic indications with
neurodegenerative components, including glaucoma,21
macular degeneration,22 and retinitis pigmentosa.23
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ETDRS ¼ Early Treatment Diabetic Retinopathy Study; mNGF ¼ murine
nerve growth factor; NGF ¼ nerve growth factor; NK ¼ neurotrophic
keratitis; PED ¼ persistent epithelial defect; rhNGF ¼ recombinant human
nerve growth factor; SE ¼ standard error; VAS ¼ visual analog scale.
Correspondence:
Alessandro Lambiase, MD, PhD, Sense Organs Department, Sapienza
University, Viale del Policlinico 155, Rome, Italy, 00100. E-mail:
alessandro.lambiase@uniroma1.it.1343
